413 Shares in Thermo Fisher Scientific Inc. (NYSE:TMO) Acquired by Bright Futures Wealth Management LLC.

Bright Futures Wealth Management LLC. purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 413 shares of the medical research company’s stock, valued at approximately $228,000.

A number of other institutional investors have also recently bought and sold shares of TMO. Northwest Financial Advisors acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. True Wealth Design LLC raised its holdings in shares of Thermo Fisher Scientific by 1,275.0% in the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 51 shares during the last quarter. LifeSteps Financial Inc. acquired a new stake in shares of Thermo Fisher Scientific in the first quarter valued at approximately $31,000. Headlands Technologies LLC acquired a new stake in shares of Thermo Fisher Scientific in the first quarter valued at approximately $32,000. Finally, Pineridge Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $39,000. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total value of $5,672,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,238,340.48. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $70,238,340.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $1,201,700.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at $7,860,920.55. The disclosure for this sale can be found here. Insiders have sold a total of 33,084 shares of company stock worth $19,767,092 in the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the topic of a number of recent analyst reports. Barclays lowered their target price on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. Stifel Nicolaus boosted their target price on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. The Goldman Sachs Group boosted their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Evercore ISI reduced their price objective on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Finally, HSBC lifted their price objective on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Five investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $618.94.

Thermo Fisher Scientific Trading Down 1.0 %

Shares of Thermo Fisher Scientific stock traded down $6.08 on Friday, hitting $615.69. The stock had a trading volume of 1,564,731 shares, compared to its average volume of 1,701,727. The firm has a market capitalization of $235.02 billion, a P/E ratio of 39.49, a PEG ratio of 2.89 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $622.30. The stock has a 50 day moving average of $565.52 and a 200 day moving average of $568.26. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. The firm had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The company’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same period in the prior year, the business earned $5.15 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.71 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.25%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.